The upper respiratory tract, alveoli, bronchi, bronchioles, trachea, pleura, and pleural cavity make up the majority of the respiratory system. One significant and potentially fatal respiratory condition is the common cold, while others include pneumonia, lung cancer, asthma, influenza, tuberculosis, etc.. A disorder is characterised as a situation when the body is not operating normally. The medical terminologies used to examine the various forms of infections, allergies, and other diseases connected to the various organs, tissues, and specialised cells of the human respiratory system include respiratory system disorders or respiratory diseases.
We are back to be better.
By delivering the most recent clinical updates and technological breakthroughs in the field of pulmonology and respiratory care, it will educate the attendees. The best forum for learning, communicating, and debating new concepts, recent discoveries, treatments, failures, and issues related to COPD and lung health will be offered at RESPIRATORY HEALTH 2023 by a group of many other multidisciplinary specialists as well as knowledgeable, skilled, and experienced pulmonologists, surgeons, healthcare professionals, and pharmaceutical companies.
RESPIRATORY HEALTH 2023 is a great venue for sharing your groundbreaking findings with a targeted audience and for spreading the word about your work to a wider audience by educating professionals in the same or related fields. The main goal is to raise awareness of lung health among the general public and to give pulmonologists a forum to share and discuss their ideas, which is important for the development of improved diagnostic and treatment approaches that will further enhance the quality of life for those who have .
- Pulmonologists
- Respiratory medicine
- Respiratory physicians
- Respiratory disease specialists
- Allergy and Immunology
- General Medicine & Internal Medicine
- Respiratory Therapy
- Radiology & Radiotherapy
- Physiotherapy
- Nursing
- Behavioural Science
- Environmental and Occupational Health
- Infectious Disease
- Paediatric Pulmonary, Critical Care, and Sleep
- Cardiology
- Tuberculosis Societies
- Radiology & Radiotherapy
- Health Care Experts
- Behavioural Science
- Infectious Disease
- Physiotherapy
- Respiratory disease specialists
- Experts of Respiratory Control Program
- Environmental and Occupational Health
The respiratory medicine market share is expected to increase by USD 26.95 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.96%. This respiratory drugs market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies, evaluate their business approaches. Furthermore, this report extensively covers respiratory drugs market segmentation by type (asthma, COPD, allergic rhinitis, cystic fibrosis, and other respiratory diseases) and geography (North America, Europe, Asia, and Rest of World
Covid Impact and recovery Analysis
A rise in the number of COVID-19 cases in the first quarter of 2020 led to partial lockdowns in several countries. Thus, some scheduled treatments were either delayed or postponed, which thus declined the adoption of various drugs, such as respiratory drugs, and impacted market growth in 2020 and Q1 2021 to some extent. However, by January 2021, following the widespread COVID-19 vaccination drive, lockdown restrictions in various countries was somewhat relaxed, which led to the resumption of business activities.
Thus, this is expected to increase the demand in the respiratory drugs market in all over the world during the forecast period.While it adversely affected the anesthesia market, respiratory market segments experienced unprecedented growth due to a continent-wide state of emergency and a surge in demand for these products. However, the effects are only temporary and are expected to correct themselves in the recovery years due to over-purchasing and a transition back to pre-pandemic conditions.
